BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:camoteskimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of camoteskimab\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07599813-1343@assetmemo.bio
DTSTAMP:20261121T005820Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:camoteskimab: Phase 2 readout est. (NCT07599813)
DESCRIPTION:camoteskimab\, phase 2\, Atopic Dermatitis.\nStudy: A Phase 2b 
 Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Ato
 pic Dermatitis\nEstimated primary completion: 31 October 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/camoteskimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07599813
URL:https://assetmemo.bio/drug/camoteskimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
